Awak Technologies is a Singapore-based patient-centric medical technology company led by CEO Suresha Venkataraya. Its core product is an ultra-portable peritoneal dialysis system that enables kidney disease patients to undergo dialysis at home or on the go. The company’s patented technologies regenerate and reconstitute waste dialysis fluid into usable fluid, reducing the amount of dialysis fluid needed by up to 90% and enabling miniaturisation of the machine to fit into a small carry bag. Awak plans to use the recent funding to complete an ongoing human pre-pivotal clinical trial, further enhance its products and portfolio, and advance toward a US-based pivotal trial and eventual US launch. The company has offices in Burbank, California and Bengaluru, India. The Series B financing (over USD$20M) supports these clinical and commercialisation efforts. AWAK Technologies develops the AWAK PD, a wearable, ultra‑portable sorbent‑based peritoneal dialysis device that removes uremic toxins from spent dialysate and reconstitutes used fluid into fresh fluid in real time. The device is lightweight (a couple of kilograms), designed for patient self‑administration without medical supervision and aims to eliminate dependence on large dialysate volumes, continuous water supply and costly water treatment. AWAK completed a first‑in‑human study in October 2018 with no serious adverse events and demonstrated effective waste removal, and the device has received FDA Breakthrough Device Designation. Proceeds from the recent financing will be used to complete a pivotal clinical trial, strengthen R&D, and prepare for manufacturing and commercialisation, with AWAK expecting to initiate a pivotal study in the next 12–18 months while engaging global regulators. The company is headquartered in Singapore with an office in Burbank, California. Financially, AWAK closed an oversubscribed US$40M financing in 2019 — the largest medtech fundraise in Singapore and among the largest in Southeast Asia — bringing total funding since inception to more than US$60M. AWAK Technologies is a Singapore medtech startup focused on developing solutions for patients with end-stage renal disease. Its core work centers on medical technologies aimed at treating or managing end-stage renal failure. The company recently secured an $11.2 million investment led by Accuron MedTech. Accuron MedTech is a division of Accuron Technologies Limited, a wholly‑owned subsidiary of Temasek Holdings. The article does not disclose the financing instrument, participation of additional investors, past rounds, revenues, or other operating metrics. The reported funding represents institutional backing from a Temasek‑linked investor as AWAK advances its medtech efforts.

Total raised

$71M

Funding rounds

3

Latest round

Series B

Latest activity

Sep 2023